Document is current
Any future updates will be listed below
-
Authors
Ono, Daisuke https://orcid.org/0000-0002-0238-7355
Sekiya, Hiroaki
Ghayal, Nikhil B.
Maier, Alexia R.
Roemer, Shanu F.
Uitti, Ryan J.
Litvan, Irene
Josephs, Keith A.
Wszolek, Zbigniew K.
Dickson, Dennis W.
-
Funding
Funding for this research was provided by:
JST BOOST Program Japan (JPMJBY24B8)
Florida Department of Health (24A08)
Rainwater Charitable Foundation
Jaye F. and Betty F. Dyer Foundation
- License Information
-
More Information
Article History
Received: 14 June 2025
Revised: 6 October 2025
Accepted: 7 October 2025
First Online: 17 October 2025
Declarations
:
: ZKW is partially supported by the NIH/NIA and NIH/NINDS (1U19AG063911, FAIN: U19AG063911), the Haworth Family Professorship in Neurodegenerative Diseases fund, The Albertson Parkinson’s Research Foundation, and PPND Family Foundation. He serves as PI or Co-PI on Biohaven Pharmaceuticals, Inc. (BHV4157-206), Vigil Neuroscience, Inc. (VGL101-01.002, VGL101-01.201, Csf1r biomarker and repository project, and ultra-high field MRI in the diagnosis and management of CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia), ONO-2808-03, and Amylyx Pharmaceuticals, Inc. (A35-009) projects/grants. He serves as Co-PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc., and as a consultant for Eli Lilly & Company and Savanna Bio. KAJ is funded by the National Institute of Neurological Disorders and Stroke (R01- NS89757) and the National Institute on Deafness and Other Communication Disorders (R01-DC14942 & R01-DC12519).
